Interview with Sven Dethlefs, CEO, TEVA Germany
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Address: Werner-von-Siemens-Straße 22-28
64625 Bensheim
Tel: +49 (0) 6251 – 1083-0
Web: http://www.koehler-chemie.de/deutsch/startseite/
Dr. Franz Köhler Chemie, the company, specialises in organ-protecting solutions, therapeutics, x-ray contrast agents and antidotes. On this basis, Dr. Gernot Köhler, from the second generation, has expanded the company into an innovative, research-intensive and high performance pharmaceuticals company in Alsbach, the USA and Russia. Distributing associates represent the company worldwide. Internal research makes innovative products and continuous development possible. As a result, new therapeutic approaches are formulated in close co-operation with qualified doctors and research is carried out effectively and dependent on requirements. “We are at your service” is the mission statement with which we shall continue to contribute to advances in science and medicine in the interests of the user and patients alike.
Dr. Franz Josef Köhler founded the company in 1959. He is the founder of aspartic therapy and a promoter of organ-protecting solutions. In his honour, the German Society for Thoracic and Cardiovascular Surgery has awarded the “Franz J. Köhler Award” every year since 1990, for outstanding work in the field of organ protection with special emphasis on the heart. His son, Dr. Gernot Köhler, has headed this modern medium sized company since 1984, guiding it into new areas of business.
Dr. Franz Köhler Chemie produces at two German locations thereby meeting the increasing international demand for organ-protecting solutions. The products, perfusion, infusion and injection solutions from Alsbach and Bensheim in South Hesse are in a leading position internationally.
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
See our Cookie Privacy Policy Here
